Ivacaftor (also referred to as VX-770), developed by Vertex Pharmaceuticals, is a highly effective CFTR potentiator approved for the treatment of lung disease in Cystic Fibrosis in patients with genetic mutations associated with decreased CFTR channel function [8]. Here, CFTR is linked to lung disorder.